
Key points:
Court rules on main charges: The federal court in Florida has upheld most of the consumer class action allegations against ZYN nicotine pouches, including design defects, insufficient warnings, and negligence.
The lawsuit focuses on deceptive marketing: Plaintiffs accuse Philip Morris International (PMI) and Swedish Match of using appealing flavors to attract young people and falsely advertising ZYN as a "safer alternative."
Nicotine addiction risk: ZYN products are believed to contain pharmaceutical-grade nicotine, with nicotine concentrations exceeding traditional replacement therapy standards.
The court dismissed some fraud allegations but allows for amendments: The judge dismissed some claims of fraud and medical monitoring, but allows plaintiffs to revise their statements and resubmit.
Defendants deny the allegations and plan to vigorously defend against remaining charges: Philip Morris International (PMI) stated that they are reviewing the judgment and intend to vigorously defend against the remaining allegations.
According to a recent report by Topclassactions, on March 19th, a federal judge in Florida allowed key allegations in two consumer class action lawsuits against Philip Morris and its subsidiary Swedish Match to proceed. These lawsuits allege that their ZYN nicotine pouch products have caused ongoing health issues and involve deceptive marketing, especially targeting young people.
In a ruling on March 19, United States District Judge William P. Dimitrouleas partially granted the defendant's motion to dismiss, dismissing a charge of fraudulent concealment on the grounds that the accusation lacked sufficient detail and failed to clearly articulate the connection between the alleged false statements and the harm suffered by the plaintiff.
However, the court upheld most of the plaintiff's allegations, including claims involving design defects, failure to warn, and negligence. The judge also rejected PMI's efforts to dismiss the lawsuit on the grounds of lack of jurisdiction, finding that the company's business activities in Florida, including marketing and selling ZYN products, provided sufficient basis for federal court to hear this case.
The ZYN class action lawsuit filed by consumers Zachary Kelly and Kovadis Palmer accuses PMI Corporation and Swedish Match Company of marketing ZYN to young people with appealing flavors and deceptively promoting it as a safe alternative to smoking and e-cigarettes. The plaintiffs claim that these nicotine pouches contain pharmaceutical-grade nicotine, leading to long-term addiction and health risks.
Kelly's class action lawsuit alleges, "Like cigarettes and e-cigarettes, ZYN is designed to create and maintain nicotine addiction. Nicotine is the fundamental reason people use these products.
Nicotine is a highly addictive drug, with addiction levels comparable to cocaine and heroin. Children, in particular, are especially prone to becoming addicted to nicotine. Nine out of ten nicotine users start before the age of 18, and over 80% of those who start during adolescence continue into adulthood. The defendant is well aware of this.
Although the judge reduced the fraud charges and denied the request for medical monitoring relief, he did give the plaintiff the opportunity to amend their accusations. Philip Morris International stated that they are reviewing the ruling and plan to mount a "vigorous defense" against the remaining charges.
The lawsuit alleges that ZYN nicotine pouch products have unreasonable dangerous characteristics.
In the ZYN lawsuit, the plaintiff accuses Philip Morris and Swedish Match of falsely claiming that ZYN is a smokeless nicotine replacement therapy that can serve as an alternative to cigarettes or e-cigarettes, despite the fact that the nicotine concentration levels in ZYN exceed those found in traditional nicotine replacement therapies.
Kelly argued that he was not aware of the unreasonable dangerous characteristics of ZYN when he first started using the product. He stated that he is now addicted to the nicotine contained in ZYN and has suffered physical harm as a result of using it.
According to a report from Law360, after a hearing in August 2024, a judge dismissed the fraud allegations and the request for medical monitoring. The report stated that the allegations were dismissed but allowed for the lawsuit to be refiled (dismissed without prejudice), giving consumers the opportunity to amend their complaint.
Last year, an anonymous plaintiff filed a class action lawsuit against Philip Morris and Swedish Match, accusing the companies of deceptively marketing their ZYN nicotine pouches as a healthy and smoking cessation device to teenagers and other consumers.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.